APA (7th ed.) Citation

Schiele, P., Kolling, S., Stintzing, S., Junkuhn, C., Walter, A., Rosnev, S., . . . Na, I. (2024). 180P FIRE-6: Longitudinal immune profiling identified disturbed NK cell functionality in RAS/BRAF wild-type metastatic colorectal cancer patients and during combined treatment with FOLFIRI, cetuximab followed by avelumab maintenance. Annals of Oncology, 35, S287. https://doi.org/10.1016/j.annonc.2024.08.2185

Chicago Style (17th ed.) Citation

Schiele, P., et al. "180P FIRE-6: Longitudinal Immune Profiling Identified Disturbed NK Cell Functionality in RAS/BRAF Wild-type Metastatic Colorectal Cancer Patients and During Combined Treatment with FOLFIRI, Cetuximab Followed by Avelumab Maintenance." Annals of Oncology 35 (2024): S287. https://doi.org/10.1016/j.annonc.2024.08.2185.

MLA (9th ed.) Citation

Schiele, P., et al. "180P FIRE-6: Longitudinal Immune Profiling Identified Disturbed NK Cell Functionality in RAS/BRAF Wild-type Metastatic Colorectal Cancer Patients and During Combined Treatment with FOLFIRI, Cetuximab Followed by Avelumab Maintenance." Annals of Oncology, vol. 35, 2024, p. S287, https://doi.org/10.1016/j.annonc.2024.08.2185.